Department of Pathology, Division of Medical Microbiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Microbiol Spectr. 2024 Oct 3;12(10):e0111624. doi: 10.1128/spectrum.01116-24. Epub 2024 Aug 20.
Respiratory disease, attributed to influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, was reported nationally during the 2023/2024 respiratory viral season. The emergence of novel SARS-CoV-2 variants was considered a significant factor contributing to the rise in COVID-19 cases. Data from the Johns Hopkins Hospital System (JHHS) showed that enterovirus/rhinovirus had also been circulating at high rates. Analyzing clinical outcomes of the most prevalent respiratory viruses is crucial for understanding the role of circulating viral genotypes. A retrospective cohort of patients who tested positive for SARS-CoV-2, influenza, RSV, or enterovirus/rhinovirus between 1 June and 31 December 2023 was included in the study. Remnant clinical samples were utilized for targeted viral whole-genome sequencing and genotyping. Patients' metadata and outcomes following infection were studied, stratified by viral variants and genotypes. The increase of SARS-CoV-2 positivity in December was associated with the predominance of JN.1. Admissions for patients under 18 years old were primarily associated with enterovirus/rhinovirus and RSV, while older age groups were mainly linked to SARS-CoV-2 and influenza infections. SARS-CoV-2-related admissions increased with the predominance of the JN.1 variant in December. No significant difference in admissions for influenza subtypes, rhinovirus species, or SARS-CoV-2 variants was observed. RSV A was associated with slightly higher odds of admission compared with RSV B. Our data highlight the importance of systematically analyzing respiratory viral infections to inform public health strategies and clinical management, especially as SARS-CoV-2 becomes endemic. The findings highlight the value of expanded genomic surveillance in elucidating the clinical significance of viral evolution.IMPORTANCEThe analysis of the epidemiology and clinical outcomes of multiple co-circulating respiratory viruses in the early 2023/2024 respiratory virus season highlights the emergence of the SARS-CoV-2 JN.1 variant as well as underscores the importance of enterovirus/rhinovirus in respiratory infections. Understanding these dynamics is essential for refining public health strategies and clinical management, especially as SARS-CoV-2 transitions to an endemic status. This work emphasizes the need for ongoing surveillance, robust diagnostic algorithms, and detailed genomic analyses to anticipate and mitigate the burden of respiratory viral infections, ultimately contributing to more informed decision-making in healthcare settings and better patient outcomes.
呼吸道疾病归因于流感、呼吸道合胞病毒(RSV)和 SARS-CoV-2,在 2023/2024 呼吸道病毒季节期间在全国范围内报告。新型 SARS-CoV-2 变体的出现被认为是导致 COVID-19 病例增加的一个重要因素。约翰霍普金斯医院系统(JHHS)的数据显示,肠病毒/鼻病毒也在以高频率传播。分析最常见的呼吸道病毒的临床结果对于了解循环病毒基因型的作用至关重要。这项研究纳入了 2023 年 6 月 1 日至 12 月 31 日期间 SARS-CoV-2、流感、RSV 或肠病毒/鼻病毒检测呈阳性的患者进行回顾性队列研究。利用剩余的临床样本进行靶向病毒全基因组测序和基因分型。研究了患者在感染后的元数据和结果,并按病毒变体和基因型进行分层。12 月 SARS-CoV-2 阳性率的增加与 JN.1 的优势有关。18 岁以下患者的住院主要与肠病毒/鼻病毒和 RSV 有关,而年龄较大的患者主要与 SARS-CoV-2 和流感感染有关。12 月,与 JN.1 变体优势相关的 SARS-CoV-2 相关住院人数有所增加。未观察到流感亚型、鼻病毒种或 SARS-CoV-2 变体的住院率有显著差异。与 RSV B 相比,RSV A 与住院的相关性稍高。我们的数据强调了系统分析呼吸道病毒感染以告知公共卫生策略和临床管理的重要性,特别是随着 SARS-CoV-2 成为地方性疾病。研究结果强调了扩展基因组监测在阐明病毒进化的临床意义方面的价值。
重要性:分析 2023/2024 呼吸道病毒季节早期多种循环呼吸道病毒的流行病学和临床结果,突出了 SARS-CoV-2 JN.1 变体的出现,并强调了肠病毒/鼻病毒在呼吸道感染中的重要性。了解这些动态对于完善公共卫生策略和临床管理至关重要,特别是随着 SARS-CoV-2 过渡到地方性疾病状态。这项工作强调了持续监测、强大的诊断算法和详细的基因组分析的必要性,以预测和减轻呼吸道病毒感染的负担,最终有助于在医疗保健环境中做出更明智的决策并改善患者预后。
Influenza Other Respir Viruses. 2025-2
Mater Today Bio. 2025-7-16
Open Forum Infect Dis. 2023-11-16
MMWR Morb Mortal Wkly Rep. 2023-4-7
Clin Infect Dis. 2023-4-3